Gallic acid grafted chitosan as well as preparation method and application thereof

Through the preparation method of gallic acid graft chitosan, antibiotic resistance and residual problems in the treatment of cow mastitis were solved, the stability and antibacterial ability of the agent were improved, and an effective treatment plan for cow mastitis was provided.

CN118994436APending Publication Date: 2024-11-22BEIJING UNIV OF AGRI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411103742.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-13
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing antibiotics in the treatment of cow mastitis are prone to the production of drug-resistant strains, antibiotic residues affect human health, and single natural compounds lack effectiveness for complex cow mastitis, and oral application leads to low drug consumption and bioavailability.

Method used

The preparation method of gallic acid graft chitosan is adopted to protect the amino group on chitosan by benzaldehyde, and coumarin-3-carboxylic acid is introduced, and the protective group is removed in the hydrochloric acid solution, and finally react with gallic acid. , forming gallic acid grafted chitosan with antibacterial and anti-inflammatory effects.

Benefits of technology

It significantly improves the stability and antioxidant ability of the agent, significantly improves the in vitro antibacterial ability of cow mastitis, and is safe for cow mammary epithelial cells, providing a new treatment direction.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004990111830000081
    Figure BDA0004990111830000081
Patent Text Reader

Abstract

The invention belongs to the technical field of animal husbandry, and provides gallic acid grafted chitosan as well as a preparation method and application thereof. The method comprises the following steps: firstly, protecting amino groups of chitosan by using benzaldehyde, and grafting coumarin-3-carboxylic acid with C6-OH on the chitosan through esterification reaction, so as to introduce coumarin-3-carboxylic acid with sterilization and anti-inflammation functions; the preparation method comprises the following steps: firstly preparing coumarin and chitosan, then mixing the obtained coumarin-chitosan in a hydrochloric acid solution, removing a protecting group on an amino group, then performing a Schiff base reaction on gallic acid and a free amino group on the chitosan in a mixed solution, and grafting the gallic acid with an antibacterial effect to the surface of the chitosan, thereby obtaining the gallic acid grafted chitosan. The coumarin-3-carboxylic acid, the gallic acid and the chitosan have antibacterial and anti-inflammatory effects, after modification, the stability of the gallic acid can be remarkably improved, the use effect of the medicament is effectively improved, and the medicament has a good inhibition effect on dairy cow mastitis pathogenic bacteria.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of animal husbandry, and in particular to gallic acid grafted chitosan and a preparation method and application thereof. Background Art

[0002] Cow mastitis refers to an inflammatory disease of the mammary tissue of cows, which is the most important factor hindering the development of the dairy industry and damaging the health of consumers. The disease is mainly caused by bacterial infection, among which Staphylococcus aureus (S.aureus) and Escherichia coli (E.coli) are the most common. At present, the treatment of mastitis mainly relies on antibiotics. However, this will produce drug-resistant strains and reduce the efficiency of treatment. At the same time, there is a problem of antibiotic residues, which seriously affects human health. Therefore, it is urgent to find a natural compound to replace antibiotics. However, a single natural compound is obviously lacking in effectiveness against cow mastitis with complex causes. Moreover, the compound is mostly used orally, which will cause the drug to be consumed in advance due to the first-pass effect of the liver, which reduces the bioavailability to a certain extent. Therefore, providing a new composite natural compound and administration method for the treatment of cow mastitis has become an urgent problem to be solved in the dairy farming industry. Summary of the invention

[0003] The purpose of the present invention is to overcome the defects of drug-resistant strains, antibiotic residues and low bioavailability generated in the process of preventing cow mastitis in the prior art, and to provide a gallic acid grafted chitosan and a preparation method and application thereof.

[0004] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0005] The present invention provides a method for preparing gallic acid grafted chitosan, comprising the following steps:

[0006] (1) reacting chitosan, acetic acid solution and benzaldehyde, and then adding sodium hydroxide solution to obtain a precipitate;

[0007] (2) subjecting the precipitate, coumarin-3-carboxylic acid, dimethyl sulfoxide and sulfuric acid solution to an esterification reaction to obtain coumarin-chitosan;

[0008] (3) placing coumarin-chitosan in a hydrochloric acid solution and mixing to obtain an intermediate;

[0009] (4) mixing 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloric acid buffer solution, N-hydroxysuccinimide and gallic acid solution to obtain a composite solution system;

[0010] (5) The intermediate solution and the composite solution system are mixed and reacted to obtain the gallic acid grafted chitosan.

[0011] Preferably, the volume fraction of the acetic acid solution in step (1) is 2-5%; the concentration of the sodium hydroxide solution is 2.5-3 mol / L;

[0012] In step (1), the mass volume ratio of chitosan, acetic acid solution, benzaldehyde and sodium hydroxide solution is 1-10 g: 300-400 mL: 5-15 mL: 100-200 mL.

[0013] Preferably, the reaction temperature in step (1) is 35-40° C. and the reaction time is 8-10 h.

[0014] Preferably, the mass fraction of the sulfuric acid solution in step (2) is 72-80%;

[0015] The mass volume ratio of chitosan in step (1) and coumarin-3-carboxylic acid, dimethyl sulfoxide and sulfuric acid solution in step (2) is 1-10 g: 0.5-1 g: 200-300 mL: 1-5 mL;

[0016] The temperature of the esterification reaction in step (2) is 50-55° C. and the time is 18-24 hours.

[0017] Preferably, the volume fraction of the hydrochloric acid solution in step (3) is 5 to 10%;

[0018] The mass volume ratio of the chitosan in step (1) to the hydrochloric acid solution in step (3) is 1-10 g: 400-500 mL;

[0019] The mixing time in step (3) is 12 to 14 hours.

[0020] Preferably, the solvent of the 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride buffer solution in step (4) is 2-(N-morpholine)ethanesulfonic acid buffer; the concentration of the 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride buffer solution is 0.14 to 0.18 g / mL;

[0021] The concentration of the gallic acid solution is 0.16-0.18 g / mL;

[0022] The mass volume ratio of chitosan in step (1) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloric acid buffer solution, N-hydroxysuccinimide and gallic acid solution in step (4) is 1-10 g: 150-200 mL: 1-1.5 g: 200-300 mL.

[0023] Preferably, the concentration of the intermediate solution in step (5) is 0.004-0.005 g / mL.

[0024] Preferably, the mixing temperature in step (5) is 0 to 5°C and the mixing time is 30 to 60 minutes;

[0025] The reaction temperature in step (5) is 20-30° C. and the reaction time is 10-14 h.

[0026] The invention also provides gallic acid grafted chitosan obtained by the preparation method.

[0027] The invention also provides the use of the gallic acid grafted chitosan in preparing a drug for preventing and treating cow mastitis.

[0028] The invention provides a preparation method of chitosan grafted with gallic acid. The invention firstly protects the amino group of chitosan with benzaldehyde, grafts coumarin-3-carboxylic acid with C6-OH on chitosan through esterification reaction, thereby introducing coumarin-3-carboxylic acid with bactericidal and anti-inflammatory functions; then the obtained coumarin-chitosan is mixed in a hydrochloric acid solution, the protecting group on the amino group is removed, and then the gallic acid is subjected to Schiff base reaction with the free amino group on the chitosan in the mixed solution, and the gallic acid with antibacterial effect is grafted onto the surface of chitosan, thereby obtaining gallic acid grafted chitosan. In the invention, coumarin-3-carboxylic acid, gallic acid and chitosan all have antibacterial and anti-inflammatory effects, and after modification, the stability can be significantly improved, the use effect of the agent can be effectively improved, the in vitro antibacterial ability for cow mastitis is good, and the cell safety is good.

[0029] The invention adopts natural raw materials, and grafts gallic acid onto chitosan by grafting modification, thereby improving the antioxidant capacity of chitosan and the solubility and stability of gallic acid. These two raw materials can be used for the prevention and treatment of cow mastitis, providing a new direction for the treatment of this disease. DETAILED DESCRIPTION

[0030] The present invention provides a method for preparing gallic acid grafted chitosan, comprising the following steps:

[0031] (1) reacting chitosan, acetic acid solution and benzaldehyde, and then adding sodium hydroxide solution to obtain a precipitate;

[0032] (2) subjecting the precipitate, coumarin-3-carboxylic acid, dimethyl sulfoxide and sulfuric acid solution to an esterification reaction to obtain coumarin-chitosan;

[0033] (3) placing coumarin-chitosan in a hydrochloric acid solution and mixing to obtain an intermediate;

[0034] (4) mixing 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloric acid buffer solution, N-hydroxysuccinimide and gallic acid solution to obtain a composite solution system;

[0035] (5) The intermediate solution and the composite solution system are mixed and reacted to obtain the gallic acid grafted chitosan.

[0036] In the present invention, the volume fraction of the acetic acid solution in step (1) is preferably 2-5%, more preferably 2.5-4.5%, and more preferably 3-4%; the concentration of the sodium hydroxide solution is preferably 2.5-3 mol / L, more preferably 2.6-2.9 mol / L, and more preferably 2.7-2.8 mol / L.

[0037] In the present invention, the mass volume ratio of chitosan, acetic acid solution, benzaldehyde and sodium hydroxide solution in step (1) is preferably 1-10 g: 300-400 mL: 5-15 mL: 100-200 mL, more preferably 2-8 g: 320-380 mL: 6-14 mL: 120-180 mL, and more preferably 4-6 g: 340-360 mL: 8-12 mL: 140-160 mL.

[0038] In the present invention, the reaction temperature in step (1) is preferably 35-40°C, more preferably 36-39°C, more preferably 37-38°C; the reaction time is preferably 8-10h, more preferably 8.5-9.5h, more preferably 8.8-9.2h.

[0039] In the present invention, after the reaction is completed, sodium hydroxide solution is added, and then filtered, washed and filtered to obtain a precipitate.

[0040] In the present invention, the mass fraction of the sulfuric acid solution in step (2) is preferably 72 to 80%, more preferably 74 to 78%, and even more preferably 75 to 77%.

[0041] In the present invention, the mass volume ratio of chitosan in step (1) and coumarin-3-carboxylic acid, dimethyl sulfoxide and sulfuric acid solution in step (2) is preferably 1-10 g: 0.5-1 g: 200-300 mL: 1-5 mL, more preferably 2-8 g: 0.6-0.9 g: 220-280 mL: 2-4 mL, and more preferably 4-6 g: 0.7-0.8 g: 240-260 mL: 2.5-3.5 mL.

[0042] In the present invention, the temperature of the esterification reaction in step (2) is preferably 50-55°C, more preferably 51-54°C, more preferably 52-53°C; the time is preferably 18-24h, more preferably 19-23h, more preferably 20-22h.

[0043] In the present invention, after the esterification reaction is completed, the coumarin-chitosan is obtained by filtering and washing.

[0044] In the present invention, the volume fraction of the hydrochloric acid solution in step (3) is preferably 5 to 10%, more preferably 6 to 9%, and even more preferably 7 to 8%.

[0045] In the present invention, the mass volume ratio of chitosan in step (1) and the hydrochloric acid solution in step (3) is preferably 1-10 g:400-500 mL, more preferably 2-8 g:420-480 mL, and more preferably 4-6 g:440-460 mL.

[0046] In the present invention, the mixing time in step (3) is preferably 12 to 14 hours, more preferably 12.5 to 13.5 hours, and more preferably 12.8 to 13.2 hours.

[0047] In the present invention, after the mixing is completed, the intermediate is obtained by suction filtration and drying.

[0048] In the present invention, the solvent of the 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride buffer solution in step (4) is 2-(N-morpholine)ethanesulfonic acid buffer; the concentration of the 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride buffer solution is preferably 0.14 to 0.18 g / mL, more preferably 0.15 to 0.17 g / mL, and more preferably 0.155 to 0.165 g / mL.

[0049] In the present invention, the solvent of the gallic acid solution is ethanol, and the concentration of the ethanol is preferably 10-50%, more preferably 20-40%, and more preferably 30-35%; the concentration of the gallic acid solution is preferably 0.16-0.18 g / mL, more preferably 0.165-0.175 g / mL, and more preferably 0.166-0.174 g / mL.

[0050] In the present invention, the mass volume ratio of chitosan in step (1) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloric acid buffer solution, N-hydroxysuccinimide and gallic acid solution in step (4) is preferably 1-10 g: 150-200 mL: 1-1.5 g: 200-300 mL, more preferably 2-8 g: 160-190 mL: 1.1-1.4 g: 220-280 mL, and more preferably 4-6 g: 170-180 mL: 1.2-1.3 g: 240-260 mL.

[0051] In the present invention, the temperature for mixing 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride buffer solution, N-hydroxysuccinimide and gallic acid solution is preferably 0-5°C, more preferably 1-4°C, more preferably 2-3°C; the time is preferably 1-1.5h, more preferably 1.1-1.4h, more preferably 1.2-1.3h.

[0052] In the present invention, the solvent of the intermediate solution is glacial acetic acid, and the concentration of the glacial acetic acid is preferably 1 to 1.5%, more preferably 1.1 to 1.4%, and even more preferably 1.2 to 1.3%.

[0053] In the present invention, the concentration of the intermediate solution in step (5) is preferably 0.004 to 0.005 g / mL, more preferably 0.0042 to 0.0048 g / mL, and even more preferably 0.0044 to 0.0046 g / mL.

[0054] In the present invention, the mixing temperature in step (5) is preferably 0-5°C, more preferably 1-4°C, and more preferably 2-3°C; the mixing time is preferably 30-60 min, more preferably 35-55 min, and more preferably 40-50 min, and stirring is maintained during the mixing process.

[0055] In the present invention, the reaction temperature in step (5) is preferably 20-30°C, more preferably 22-28°C, more preferably 24-26°C; the reaction time is preferably 10-14h, more preferably 10.5-13.5h, more preferably 11-13h.

[0056] In the present invention, after the reaction is completed, dialysis is performed using ultrapure water, and the molecular weight of the dialysis is preferably 3000-4000Da, more preferably 3200-3800Da, and more preferably 3400-3600Da; the dialysis time is preferably 65-75h, more preferably 66-74h, and more preferably 68-72h.

[0057] The invention also provides gallic acid grafted chitosan obtained by the preparation method.

[0058] The invention also provides the use of the gallic acid grafted chitosan in preparing a drug for preventing and treating cow mastitis.

[0059] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0060] Example 1

[0061] 5g of chitosan, 350mL of acetic acid solution (volume fraction of 3%), and 10mL of benzaldehyde were mixed and reacted at 40°C for 9h, and then 150mL of sodium hydroxide solution (concentration of 2.5mol / L) was added to produce a precipitate in the system, which was then filtered, washed, and filtered to obtain the precipitate. The precipitate, 0.6g of coumarin-3-carboxylic acid, 240mL of dimethyl sulfoxide, and 3mL of sulfuric acid solution (mass fraction of 76%) were mixed, and esterification reaction was carried out at 50°C for 20h, and coumarin-chitosan was obtained by filtering and washing; coumarin-chitosan was placed in 450mL of hydrochloric acid solution (volume fraction of 8%) and mixed for 13h, and filtered and dried to obtain an intermediate.

[0062] 180 mL of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloric acid buffer solution (the solvent is 2-(N-morpholine)ethanesulfonic acid buffer solution, the concentration is 0.16 g / mL), 260 mL of gallic acid solution (the concentration is 0.17 g / mL) and 1.4 g of N-hydroxysuccinimide are prepared with 40% ethanol, and the mixture is mixed at 2° C. for 1.2 h to obtain a composite solution system; then, 1.3% glacial acetic acid is used to prepare an intermediate solution (the concentration is 0.0042 g / mL), the intermediate solution and the composite solution system are mixed at 2° C. for 40 min, and then reacted at 25° C. for 12 h. After the reaction is completed, ultrapure water is used for dialysis, and the molecular weight is 3500 Da, and the chitosan grafted with gallic acid is obtained after dialysis for 70 h.

[0063] Example 2

[0064] 8g of chitosan, 330mL of acetic acid solution (volume fraction of 2%), and 13mL of benzaldehyde were mixed and reacted at 38°C for 8h, and then 130mL of sodium hydroxide solution (concentration of 2.7mol / L) was added to produce a precipitate in the system, which was then filtered, washed, and filtered to obtain the precipitate. The precipitate, 0.8g of coumarin-3-carboxylic acid, 240mL of dimethyl sulfoxide, and 4mL of sulfuric acid solution (mass fraction of 74%) were mixed, and esterification reaction was carried out at 55°C for 18h, and coumarin-chitosan was obtained by filtering and washing; coumarin-chitosan was placed in 470mL of hydrochloric acid solution (volume fraction of 6%) and mixed for 12h, and filtered and dried to obtain an intermediate.

[0065] 160 mL of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloric acid buffer solution (the solvent is 2-(N-morpholine)ethanesulfonic acid buffer solution, the concentration is 0.15 g / mL), 280 mL of gallic acid solution (the concentration is 0.16 g / mL) and 1.2 g of N-hydroxysuccinimide are prepared with 15% ethanol and mixed at 3°C ​​for 1.5 hours to obtain a composite solution system; then, an intermediate solution (the concentration is 0.005 g / mL) is prepared with 1% glacial acetic acid, the intermediate solution and the composite solution system are mixed at 3°C ​​for 50 minutes, and then reacted at 26°C for 14 hours. After the reaction is completed, ultrapure water is used for dialysis, and the molecular weight is 3000Da. After dialysis for 65 hours, gallic acid-grafted chitosan is obtained.

[0066] Example 3

[0067] 2g of chitosan, 360mL of acetic acid solution (volume fraction of 3%), and 7mL of benzaldehyde were mixed and reacted at 36°C for 10h, and then 140mL of sodium hydroxide solution (concentration of 3mol / L) was added to produce a precipitate in the system, which was then filtered, washed, and filtered to obtain the precipitate. The precipitate, 1g of coumarin-3-carboxylic acid, 300mL of dimethyl sulfoxide, and 2mL of sulfuric acid solution (mass fraction of 76%) were mixed, and esterification reaction was carried out at 50°C for 22h, and coumarin-chitosan was obtained by filtration and washing; coumarin-chitosan was placed in 420mL of hydrochloric acid solution (volume fraction of 8%) and mixed for 14h, and filtered and dried to obtain an intermediate.

[0068] 190 mL of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloric acid buffer solution (the solvent is 2-(N-morpholine)ethanesulfonic acid buffer solution, the concentration is 0.17 g / mL), 210 mL of gallic acid solution (the concentration is 0.18 g / mL) and 1.4 g of N-hydroxysuccinimide are prepared with 45% ethanol, and the mixture is mixed at 4°C for 1.3 h to obtain a composite solution system; then, an intermediate solution (the concentration is 0.005 g / mL) is prepared with 1.2% glacial acetic acid, the intermediate solution and the composite solution system are mixed at 4°C for 40 min, and then reacted at 30°C for 12 h. After the reaction is completed, ultrapure water is used for dialysis, and the molecular weight is 3800 Da, and the chitosan grafted with gallic acid is obtained after dialysis for 68 h.

[0069] Antimicrobial activity research performance testing

[0070] Bovine Staphylococcus aureus (S. aureus) ATCC 29740 and Escherichia coli (E. coli) CVCC 1450 were purchased from CVCC.

[0071] Preparation of bacterial suspension

[0072] S. aureus ATCC 29740 and E. coli CVCC 1450 were cultured overnight to the logarithmic growth phase, and the test bacterial solution was diluted 10 times to 10 with sterile broth medium. -5 , 10 -6 , 10 -7 , 10 -8 Then, 10 μL of the diluted bacterial solution was dropped onto the surface of the solid culture medium and cultured in a 37°C incubator for 24 h before counting the colonies. Finally, 3 to 6×10 5 CFU / mL and 1×10 8 The bacterial solution with CFU / mL was used for subsequent experiments.

[0073] 0.05 g of the gallic acid grafted chitosan prepared in Examples 1 to 3 was dissolved in 50 mL of acetic acid solution (1%, v / v) to prepare a 1 mg / mL gallic acid grafted chitosan stock solution, which was then diluted twice with sterile broth medium to obtain sample solutions with concentrations of 1, 0.5, 0.25, 0.125, 0.0625, and 0.03125 mg / mL.

[0074] 100 μL of the prepared test solution of different concentrations was added to the first 10 wells of the 96-well plate, and then the same volume of the test bacterial solution (3-6×10 5 CFU / mL), and the last two wells were added with 200μL bacterial suspension (containing 100μL fresh broth medium and 100μL of the test bacterial solution) and 200μL broth medium as positive and negative controls. Place in an incubator at 37°C for 24h and observe. The last clear well with no bacterial growth is the minimum inhibitory concentration. Take 10μL of the liquid from all clear wells and drop it on the solid culture medium. The last well with no bacterial growth is the minimum bactericidal concentration. Each group of tests was repeated 3 times, and the results are shown in Table 1. It can be seen from Table 1 that the gallic acid grafted chitosan prepared in the embodiment has excellent inhibitory effects on bovine Staphylococcus aureus and Escherichia coli.

[0075] Table 1 In vitro antibacterial results of gallic acid grafted chitosan in Examples 1 to 3

[0076]

[0077] Determination of inhibition zone diameter

[0078] Using the Kirby-Bauer disk diffusion method, 0.20 mL of 1×10 8The test bacterial suspension of CFU / mL was evenly coated on MH(A) medium, and then the paper pieces of gallic acid grafted chitosan of Examples 1 to 3 with a concentration of 1 mg / mL were attached respectively, and the diameter of the inhibition zone was measured after overnight culture at 37°C for 18 to 24 hours. The data results are recorded in Table 2. It can be seen from Table 2 that, from the perspective of the diameter of the inhibition zone, the gallic acid grafted chitosan has excellent antibacterial activity, and the diameter of the inhibition zone for S. aureus ATCC 29740 reaches 14.21±0.74mm, and the diameter of the inhibition zone for E. coli CVCC 1450 reaches 8.30±0.36mm.

[0079] Table 2 Diameter of inhibition zone of gallic acid grafted chitosan in Examples 1 to 3

[0080] S.Aureus(mm) E.Coli(mm) Example 1 14.16±0.21 8.21±0.14 Example 2 14.07±0.52 8.03±0.27 Example 3 14.21±0.74 8.30±0.36

[0081] Cell safety test

[0082] Cell culture: Bovine mammary epithelial cells (BMECs) were cultured in DMEM / F-12 (mixed in equal volumes) containing 10% FBS and 1% penicillin-streptomycin, and the cells were cultured in a 37°C, 5% CO2 incubator until the logarithmic growth phase. In the experiment, maintenance medium (containing 2% FBS) was used for cell culture.

[0083] Preparation of drug solution: Take the gallic acid grafted chitosan prepared in Example and dilute it to 150 μg / mL with complete culture medium.

[0084] 100 μL of drug was added to each well, and the drug was incubated with BMECs cells. Different treatment groups were set for 12 and 24 hours. A blank group (only culture medium) and a control group (drug concentration was 0) were set on the 96-well plate. The cells were washed with PBS, 10 μL of CCK-8 and 90 μL of maintenance culture medium were added to each well, and the 96-well plate was placed in a constant temperature incubator (37°C, 5% CO2) and cultured for 4 hours. The absorbance value was detected at 450 nm using an ELISA reader, and the cell viability was calculated according to the following formula. The results are shown in Table 3.

[0085] Cell viability = (OD1-OD0) / (OD2-OD0) × 100%;

[0086] Wherein: OD0 is the OD value of the blank group; OD1 is the OD value of the experimental group; OD2 is the OD value of the control group.

[0087] Table 3 Cell safety results of gallic acid grafted chitosan in Examples 1 to 3

[0088] Case 12h cell viability (%) 24h cell viability (%) Example 1 102.5 101.6 Example 2 101.3 104.1 Example 3 103.2 103.4

[0089] As can be seen from Table 3, the cell viability of the gallic acid grafted chitosan prepared in the examples at 150 μg / mL was higher than 100%, indicating that the gallic acid grafted chitosan prepared in the examples had no cytotoxicity to bovine mammary epithelial cells and was safe and reliable.

[0090] It can be seen from the above embodiments that the present invention provides a method for preparing gallic acid grafted chitosan. In the present invention, coumarin-3-carboxylic acid, gallic acid and chitosan all have antibacterial and anti-inflammatory effects, and after modification, the stability can be significantly improved, the use effect of the agent can be effectively improved, and the agent has good in vitro antibacterial ability against bovine mastitis, and has good cell safety, no cytotoxicity, and is safe and reliable.

[0091] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A method for preparing gallic acid grafted chitosan, characterized in that: It includes the following steps: (1) reacting chitosan, acetic acid solution and benzaldehyde, and then adding sodium hydroxide solution to obtain a precipitate; (2) subjecting the precipitate, coumarin-3-carboxylic acid, dimethyl sulfoxide and sulfuric acid solution to an esterification reaction to obtain coumarin-chitosan; (3) placing coumarin-chitosan in a hydrochloric acid solution and mixing to obtain an intermediate; (4) mixing 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloric acid buffer solution, N-hydroxysuccinimide and gallic acid solution to obtain a composite solution system; (5) The intermediate solution and the composite solution system are mixed and reacted to obtain the gallic acid grafted chitosan.

2. The method for preparing gallic acid grafted chitosan according to claim 1, characterized in that: The volume fraction of the acetic acid solution in step (1) is 2-5%; the concentration of the sodium hydroxide solution is 2.5-3 mol / L; In step (1), the mass volume ratio of chitosan, acetic acid solution, benzaldehyde and sodium hydroxide solution is 1-10 g: 300-400 mL: 5-15 mL: 100-200 mL.

3. The method for preparing gallic acid grafted chitosan according to claim 1 or 2, characterized in that: The reaction temperature in step (1) is 35-40° C. and the reaction time is 8-10 h.

4. The method for preparing gallic acid grafted chitosan according to claim 3, characterized in that: The mass fraction of the sulfuric acid solution in step (2) is 72-80%; The mass volume ratio of chitosan in step (1) and coumarin-3-carboxylic acid, dimethyl sulfoxide and sulfuric acid solution in step (2) is 1-10 g: 0.5-1 g: 200-300 mL: 1-5 mL; The temperature of the esterification reaction in step (2) is 50-55° C. and the time is 18-24 hours.

5. The method for preparing gallic acid grafted chitosan according to claim 1 or 4, characterized in that: The volume fraction of the hydrochloric acid solution in step (3) is 5 to 10%; The mass volume ratio of the chitosan in step (1) to the hydrochloric acid solution in step (3) is 1-10 g: 400-500 mL; The mixing time in step (3) is 12 to 14 hours.

6. The method for preparing gallic acid grafted chitosan according to claim 5, characterized in that: The solvent of the 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride buffer solution in step (4) is 2-(N-morpholine)ethanesulfonic acid buffer; the concentration of the 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride buffer solution is 0.14 to 0.18 g / mL; The concentration of the gallic acid solution is 0.16-0.18 g / mL; The mass volume ratio of chitosan in step (1) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloric acid buffer solution, N-hydroxysuccinimide and gallic acid solution in step (4) is 1-10 g: 150-200 mL: 1-1.5 g: 200-300 mL.

7. The method for preparing gallic acid grafted chitosan as claimed in claim 1, characterized in that: The concentration of the intermediate solution in step (5) is 0.004-0.005 g / mL.

8. The method for preparing gallic acid grafted chitosan according to claim 7, characterized in that: The mixing temperature in step (5) is 0 to 5°C and the mixing time is 30 to 60 minutes; The reaction temperature in step (5) is 20-30° C. and the reaction time is 10-14 h.

9. Gallic acid grafted chitosan obtained by the preparation method according to any one of claims 1 to 8.

10. Use of the gallic acid grafted chitosan according to claim 9 in preparing a drug for preventing and treating mastitis in dairy cows.